tiprankstipranks
Definium Therapeutics, Inc. (DE:MMQ0)
NASDAQ:MMQ0
Germany Market
MMQ0
Definium Therapeutics
RESEARCH TOOLSreports

Definium Therapeutics (MMQ0) Stock Forecast & Price Target

13 Followers
See the Price Targets and Ratings of:

MMQ0 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Definium
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MMQ0 Stock 12 Month Forecast

Average Price Target

€47.64
▲(152.72% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is €47.64 with a high forecast of €64.88 and a low forecast of €26.30. The average price target represents a 152.72% change from the last price of €18.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","65":"€65","19.25":"€19.25","34.5":"€34.5","49.75":"€49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64.88097852,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€64.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.637835579999994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€47.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.3030994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,19.25,34.5,49.75,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.4,23.82161373230769,27.243227464615384,30.664841196923078,34.08645492923077,37.50806866153846,40.92968239384615,44.35129612615385,47.77290985846154,51.19452359076923,54.61613732307692,58.03775105538462,61.45936478769231,{"y":64.88097852,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.4,22.49521812153846,24.590436243076923,26.68565436461538,28.780872486153843,30.876090607692305,32.97130872923076,35.06652685076922,37.16174497230769,39.25696309384615,41.35218121538461,43.44739933692307,45.542617458461535,{"y":47.637835579999994,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.4,20.854084569230768,21.308169138461537,21.762253707692306,22.216338276923075,22.670422846153844,23.124507415384613,23.578591984615386,24.032676553846155,24.486761123076924,24.940845692307693,25.394930261538462,25.84901483076923,{"y":26.3030994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€64.88Average Price Target€47.64Lowest Price Target€26.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:MMQ0
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€26.3
Buy
39.54%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)
Canaccord Genuity Analyst forecast on DE:MMQ0
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€52.61→€50.85
Buy
169.78%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Atricure (ATRC)
LifeSci Capital Analyst forecast on DE:MMQ0
Francois Brisebois
LifeSci Capital
LifeSci Capital
€38.58→€55.24
Buy
193.03%
Upside
Reiterated
06/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:MMQ0
Ami Fadia
Needham
Needham
€33.32→€43.84
Buy
132.56%
Upside
Assigned
06/23/26
Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
H.C. Wainwright Analyst forecast on DE:MMQ0
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€61.37
Buy
225.59%
Upside
Reiterated
06/23/26
Definium: Buy Rating Reiterated on Strong EMERGE Phase 3 Data; $70 Price Target Maintained
JonesTrading Analyst forecast on DE:MMQ0
Justin Walsh
JonesTrading
JonesTrading
€53.48→€64.88
Buy
244.20%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)
Robert W. Baird Analyst forecast on DE:MMQ0
Christopher Chen
Robert W. Baird
Not Ranked
Robert W. Baird
€32.44→€49.98
Buy
165.12%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Maxim Group Analyst forecast on DE:MMQ0
Michael Okunewitch
Maxim Group
Maxim Group
€35.07→€43.84
Buy
132.56%
Upside
Assigned
06/23/26
Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment
Oppenheimer Analyst forecast on DE:MMQ0
Jay Olson
Oppenheimer
Oppenheimer
€35.07→€52.61
Buy
179.08%
Upside
Reiterated
06/22/26
Definium Therapeutics price target raised to $60 from $40 at OppenheimerDefinium Therapeutics price target raised to $60 from $40 at Oppenheimer
Jefferies Analyst forecast on DE:MMQ0
Andrew Tsai
Jefferies
Jefferies
€26.3→€30.69
Buy
62.80%
Upside
Assigned
06/22/26
Definium can climb 50%-100% after 'robust' MDD data, says JefferiesDefinium can climb 50%-100% after 'robust' MDD data, says Jefferies
RBC Capital Analyst forecast on DE:MMQ0
Brian Abrahams
RBC Capital
RBC Capital
€31.56→€49.98
Buy
165.12%
Upside
Reiterated
06/22/26
RBC Capital says would buy Definium Therapeutics after Phase III dataRBC Capital says would buy Definium Therapeutics after Phase III data
Piper Sandler Analyst forecast on DE:MMQ0
David Amsellem
Piper Sandler
Piper Sandler
€42.96→€42.08
Buy
123.26%
Upside
Reiterated
05/08/26
Definium Therapeutics price target lowered to $48 from $49 at Piper SandlerDefinium Therapeutics price target lowered to $48 from $49 at Piper Sandler
Evercore ISI Analyst forecast on DE:MMQ0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€21.04→€22.8
Buy
20.93%
Upside
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
Wolfe Research Analyst forecast on DE:MMQ0
Rudy Li
Wolfe Research
Wolfe Research
€21.92
Buy
16.28%
Upside
Initiated
02/23/26
Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research
Roth MKM Analyst forecast on DE:MMQ0
Jason Wittes
Roth MKM
Roth MKM
€31.56
Buy
67.45%
Upside
Reiterated
08/04/25
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:MMQ0
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€26.3
Buy
39.54%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)
Canaccord Genuity Analyst forecast on DE:MMQ0
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€52.61→€50.85
Buy
169.78%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Atricure (ATRC)
LifeSci Capital Analyst forecast on DE:MMQ0
Francois Brisebois
LifeSci Capital
LifeSci Capital
€38.58→€55.24
Buy
193.03%
Upside
Reiterated
06/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:MMQ0
Ami Fadia
Needham
Needham
€33.32→€43.84
Buy
132.56%
Upside
Assigned
06/23/26
Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
H.C. Wainwright Analyst forecast on DE:MMQ0
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€61.37
Buy
225.59%
Upside
Reiterated
06/23/26
Definium: Buy Rating Reiterated on Strong EMERGE Phase 3 Data; $70 Price Target Maintained
JonesTrading Analyst forecast on DE:MMQ0
Justin Walsh
JonesTrading
JonesTrading
€53.48→€64.88
Buy
244.20%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)
Robert W. Baird Analyst forecast on DE:MMQ0
Christopher Chen
Robert W. Baird
Not Ranked
Robert W. Baird
€32.44→€49.98
Buy
165.12%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Maxim Group Analyst forecast on DE:MMQ0
Michael Okunewitch
Maxim Group
Maxim Group
€35.07→€43.84
Buy
132.56%
Upside
Assigned
06/23/26
Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment
Oppenheimer Analyst forecast on DE:MMQ0
Jay Olson
Oppenheimer
Oppenheimer
€35.07→€52.61
Buy
179.08%
Upside
Reiterated
06/22/26
Definium Therapeutics price target raised to $60 from $40 at OppenheimerDefinium Therapeutics price target raised to $60 from $40 at Oppenheimer
Jefferies Analyst forecast on DE:MMQ0
Andrew Tsai
Jefferies
Jefferies
€26.3→€30.69
Buy
62.80%
Upside
Assigned
06/22/26
Definium can climb 50%-100% after 'robust' MDD data, says JefferiesDefinium can climb 50%-100% after 'robust' MDD data, says Jefferies
RBC Capital Analyst forecast on DE:MMQ0
Brian Abrahams
RBC Capital
RBC Capital
€31.56→€49.98
Buy
165.12%
Upside
Reiterated
06/22/26
RBC Capital says would buy Definium Therapeutics after Phase III dataRBC Capital says would buy Definium Therapeutics after Phase III data
Piper Sandler Analyst forecast on DE:MMQ0
David Amsellem
Piper Sandler
Piper Sandler
€42.96→€42.08
Buy
123.26%
Upside
Reiterated
05/08/26
Definium Therapeutics price target lowered to $48 from $49 at Piper SandlerDefinium Therapeutics price target lowered to $48 from $49 at Piper Sandler
Evercore ISI Analyst forecast on DE:MMQ0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€21.04→€22.8
Buy
20.93%
Upside
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
Wolfe Research Analyst forecast on DE:MMQ0
Rudy Li
Wolfe Research
Wolfe Research
€21.92
Buy
16.28%
Upside
Initiated
02/23/26
Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research
Roth MKM Analyst forecast on DE:MMQ0
Jason Wittes
Roth MKM
Roth MKM
€31.56
Buy
67.45%
Upside
Reiterated
08/04/25
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months
Sumant KulkarniCanaccord Genuity
Success Rate
11/13 ratings generated profit
85%
Average Return
+44.58%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +44.58% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
16/18 ratings generated profit
89%
Average Return
+142.91%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +142.91% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
18/18 ratings generated profit
100%
Average Return
+329.62%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +329.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MMQ0 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
15
16
25
31
37
Buy
4
3
7
5
15
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
19
32
36
52
In the current month, MMQ0 has received 52 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MMQ0 average Analyst price target in the past 3 months is 47.64.
Each month's total comprises the sum of three months' worth of ratings.

MMQ0 Financial Forecast

MMQ0 Earnings Forecast

Next quarter’s earnings estimate for MMQ0 is -€0.49 with a range of -€0.63 to -€0.38. The previous quarter’s EPS was -€0.62. MMQ0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for MMQ0 is -€0.49 with a range of -€0.63 to -€0.38. The previous quarter’s EPS was -€0.62. MMQ0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
No data currently available

MMQ0 Sales Forecast

Next quarter’s sales forecast for MMQ0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
Next quarter’s sales forecast for MMQ0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.

MMQ0 Stock Forecast FAQ

What is DE:MMQ0’s average 12-month price target, according to analysts?
Based on analyst ratings, Definium Therapeutics, Inc.’s 12-month average price target is 47.64.
    What is DE:MMQ0’s upside potential, based on the analysts’ average price target?
    Definium Therapeutics, Inc. has 152.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Definium Therapeutics, Inc. a Buy, Sell or Hold?
          Definium Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Definium Therapeutics, Inc.’s share price target?
            The average share price target for Definium Therapeutics, Inc. is 47.64. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €64.88 ,and the lowest forecast is €26.30. The average share price target represents 152.72% Increase from the current price of €18.85.
              What do analysts say about Definium Therapeutics, Inc.?
              Definium Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Definium Therapeutics, Inc.?
                To buy shares of DE:MMQ0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.